
Bureaucratic Reputation
“Conflicting Interpretations and FDA Reputation: The Case of Post-Market Surveillance of Breast Implants.”. Frontiers in Medicines, Sec. Regulatory Science. 11. https://doi.org/10.3389/fmed.2024.1475992. Publisher's Version
. 2024.
“The reputational dividends of collaborating with a highly reputable agency: The case of interagency collaboration between the U.S. FDA and its domestic partner agencies”. Public Administration Review 83(3): 639-653. https://onlinelibrary.wiley.com/doi/abs/10.1111/puar.13597. Publisher's VersionAbstract
. 2023.
“Taking stock: Strategic communication by regulatory agencies as a form of reputation management”. In Handbook on Regulatory Authorities, . Cheltenham, UK: Edward Elgar Publishing, p. 272-283.
. 2022.
“Strategic silence”. In The SAGE Encyclopedia of Corporate Reputation, . Thousand Oaks,, CA: SAGE Publications, Inc, p. 823–824. https://sk.sagepub.com/reference/the-sage-encyclopedia-of-corporate-reputation/i10244.xml. Publisher's Version
. 2016.
“Missing areas in the bureaucratic reputation framework”. Politics and Governance 4(2): 80–90. https://www.cogitatiopress.com/politicsandgovernance/article/view/570. Publisher's Version
. 2016.
“Responsive change: Agency output response to reputational threats”. Journal of Public Administration Research and Theory 26(1): 31-44. https://doi.org/10.1093/jopart/muv001. Publisher's Version
. 2015.
“Theorizing bureaucratic reputation”. In Organizational Reputation in the Public Sector, . London: Routledge, p. 17–36.
. 2015.
“Organizational reputation, regulatory talk, and strategic silence”. Journal of Public Administration Research and Theory 23(3): 581-608. https://doi.org/10.1093/jopart/mus047. Publisher's Version
. 2013.
“Organizational reputation, the content of public allegations, and regulatory communication”. Journal of Public Administration Research and Theory 25(2): 451-478. https://doi.org/10.1093/jopart/mut041. Publisher's Version
. 2013.